AUTHORS
Aaron C. Logan, MD, PhD, MPhil, Claire Roddie, MBChB, PhD2, Elias Jabbour, MD3, Deborah Cluxton4, Justin Shang5, Eric Xue6, Yiyun Zhang7, Prashant Joshi, MD8, James Grantham9, Steve Kleiboeker, DVM, PhD10, Pierre Lao-Sirieix, PhD11, Karamjeet Singh Sandhu, MD12
AFFILIATIONS
1 Hematology, Blood and Marrow Transplantation, and Cellular Therapy Program, University of California San Francisco, San Francisco, California, United States
2 University College London Cancer Institute, London, United Kingdom
3 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 Autolus Therapeutics, London, United Kingdom
5 Autolus Therapeutics, Rockville, Maryland, United States
6 Autolus Therapeutics, Rockville, Maryland, United States
7 Autolus Therapeutics, Rockville, Maryland, United States
8 Autolus Therapeutics, Rockville, Maryland, United States
9 Research and Development, Eurofins Viracor, Lenexa, Kansas, United States
10 Research and Development, Eurofins Viracor, Lenexa, Kansas, United States
11 Autolus Therapeutics, London, United Kingdom
12 City of Hope National Medical Center, Duarte, California, United States
ABSTRACT
Introduction
Obe-cel is an autologous fast off-rate CD19-directed 4-1BB-ζ chimeric antigen receptor (CAR) T-cell therapy, designed to improve persistence and minimize severe immunotoxicity. In the Phase Ib/II FELIX study (NCT04404660; Roddie et al. NEJM 2024) of obe-cel in adult patients with R/R B-ALL, continued CAR T-cell persistence at Month 3 (M3), assessed using a ddPCR assay quantifying vector transgene concentration in blood samples, was associated with improved event-free survival (EFS; Roddie et al. Cancer Res Commun 2026) and overall survival (OS; Roddie et al. Blood 2025). Recently, a novel qPCR assay was developed, validated, and made available in a reference laboratory to enable monitoring of obe-cel levels in patients subsequent to infusion (Grantham et al. Transplant Cell Ther 2026). Here, the analytical and clinical concordance between trial-associated ddPCR and the clinical-grade qPCR assays were assessed.
Methods
In FELIX, patients aged ≥18 years with R/R B-ALL underwent lymphodepletion, followed by tumor burden-guided infusions of obe-cel to a total target dose of 410×106 CAR T-cells. ddPCR was used to assess CAR transgene levels in peripheral blood samples from patients infused with obe-cel (N=127). Vector copy number (VCN) per diploid genome was determined through duplex detection of the lentiviral vector Ψ region and the endogenous reference gene, RPP30. A total of 94 samples from the FELIX study, including all samples with valid ddPCR results at M3 and available material, were selected to ensure a range of VCN/µg DNA and were re-tested with the qPCR assay (Eurofins-Viracor, Lenexa, KS). VCN quantification was performed using CAT19 and RNase P DNA standards. Concordance was assessed between the assays in the quantifiable range, and a landmark analysis was performed for EFS using persistence of detectable vector at M3, using the ddPCR and/or qPCR assays in patients with ongoing remission.
Results
A moderate to strong concordance between the two assays was observed, with a concordance correlation coefficient of 0.978 and a Pearson’s correlation coefficient of 0.999 (including all 94 samples). Additionally, 17/27 ddPCR-negative samples were found to have very low CAR levels by the qPCR assay, with a VCN between the lower limit of quantification [LLoQ] of the qPCR assay and 171 copies/µg DNA. This finding, together with the fact that the VCN values obtained using qPCR were consistently slightly higher than those obtained by ddPCR, suggests higher sensitivity of the qPCR assay.
Among the M3 samples, n=62 had matched results between ddPCR and qPCR assays. Given the small number of samples with a negative persistence result at M3 by qPCR (n=7), different cut-offs were applied to the VCN by qPCR to assess EFS according to M3 persistence. Incrementally increasing cut-offs, ranging from LLoQ to 700 VCN/µg DNA, were evaluated by calculating the hazard ratio (HR) for EFS between patients who lost persistence (< cut-off) or those with continued persistence (≥ cut-off). Using qPCR negativity versus positivity (< or ≥LLoQ; n=7 and n=55, respectively), or cut-off of < or ≥100 copies/µg DNA (n=15 and n=47, respectively), and < or ≥250 copies/µg DNA (n=22 and n=40, respectively), the HRs (95% CI) for EFS were 1.34 (0.32–5.73), 2.47 (0.97–6.30) and 2.76 (1.23–6.16). Corresponding median EFS (months [95% CI]) was NE vs 44.6 (12.32–NE), 8.1 (5.75–NE) vs 44.6 (14.98–NE) and 11.7 (6.57–NE) vs 44.6 (17.94–NE), respectively, with a progressive reduction of separation between the KM curves. Increasing the cut-off beyond 250 VCN/µg DNA did not increase the HR further.
Conclusions
Concordance between the ddPCR and qPCR assay results within this subset of patients from FELIX is sufficient and acceptable to support the use of the commercially available qPCR assay (Eurofins Viracor) to monitor obe-cel persistence in clinical practice. Detectable persistence at M3 post obe-cel infusion measured using the qPCR assay, was associated with a longer median EFS compared with loss of/undetectable persistence. The small number of samples in the analyses presented precludes any conclusion on the most appropriate VCN cut-off to determine maximum differentiation in median EFS and further investigation is therefore warranted.
DISCLOSURES
Aaron C. Logan, MD, PhD, MPhil: Kite/Gilead - Research Funding; Autolus - Research Funding; Astellas Pharma - Research Funding; Amgen - Research Funding; Takeda - Consultancy (Includes expert testimony); Adaptive Biotechnology - Consultancy (Includes expert testimony); Syntax - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Cabaletta Bio - Consultancy (Includes expert testimony); Orca - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony)